Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1733 participants.
Also called NCT02791230
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,733 participants
- Sponsor
- Registry
-
NCT02791230 -
2016-000868-42
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hong Kong SAR China, Italy, Japan, Netherlands, Spain, Sweden, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02791230. Allocation not applicable; no masking; primary purpose treatment. Start 2016-06-13 (actual); primary completion 2023-10-26 (actual). Results posted on 2025-02-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy
- Condition
- Transthyretin (TTR) Amyloid Cardiomyopathy
- Intervention (Drug)
- Tafamidis
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct02791230- Content hash
d69fc68f20d47695927d1d5cd2dd07865f03bdd3280acad4692b1867a310af62